COVID-19疫苗接种后死亡风险:自控病例系列研究
该研究采用改良自控病例系列设计,分析2020年12月14日至2021年8月11日期间八个疫苗安全数据链站点所有死亡者,评估三种COVID-19疫苗全程接种后非COVID-19死亡、全因死亡及四项心脏相关死亡结局的风险。结果显示,在调整时间趋势后,未发现接种者死亡风险增加。
要点
- 采用改良自控病例系列设计并调整时间趋势,评估接种后死亡风险。
- 辉瑞-BioNTech疫苗各结局相对发病率均低于1且95%CI不包含1。
- 莫德纳和杨森疫苗部分心脏相关死亡结局的95%CI包含1,未见风险增加。
核心结论
- 采用改良自控病例系列设计并调整时间趋势后,未发现美国使用的三种COVID-19疫苗接种者非COVID-19死亡、全因死亡及四项心脏相关死亡结局的风险增加。
研究设计与样本
- 研究分析了2020年12月14日至2021年8月11日期间八个疫苗安全数据链站点的所有死亡者。
- 采用改良自控病例系列(SCCS)设计,按疫苗类型和死亡结局进行分析,并报告相对发病率(RI)。
- 观察期从紧急使用授权日期至研究截止日(2021年8月11日),死亡后不删失观察期。
- 预先设定主要风险区间为每剂接种后28天,次要风险区间为14天。
- 将未接种者死亡纳入SCCS分析,通过在模型中纳入日历月份调整死亡率的季节性。
主要发现
- 辉瑞-BioNTech(BNT162b2)疫苗:非COVID-19死亡、全因死亡及四项心脏相关死亡结局的RI均低于1,且95%CI不包含1。
- 莫德纳(mRNA-1273)疫苗:所有结局的RI点估计均低于1,但第二剂后14天在无既往癌症和心脏病个体中,心脏相关死亡(RI=0.78,95%CI 0.58-1.04)和非COVID-19心脏相关死亡(RI=0.80,95%CI 0.60-1.08)的95%CI包含1。
- 杨森(Ad26.COV2.S)疫苗:四项心脏相关死亡结局的RI在14天风险区间为0.94至0.98,在28天风险区间为0.68至0.72,95%CI均包含1。
关键数值与推荐
- 主要风险区间:每剂接种后28天;次要风险区间:每剂接种后14天。
- 辉瑞-BioNTech疫苗各结局RI低于1且95%CI不包含1。
- 莫德纳疫苗第二剂后14天心脏相关死亡RI=0.78(95%CI 0.58-1.04),非COVID-19心脏相关死亡RI=0.80(95%CI 0.60-1.08)。
- 杨森疫苗心脏相关死亡RI在14天区间为0.94至0.98,28天区间为0.68至0.72,95%CI均包含1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although previous studies found no-increased mortality risk after COVID-19 vaccination, residual confounding bias might have impacted the findings. Using a modified self-controlled case series (SCCS) design, we assessed the risk of non-COVID-19 mortality, all-cause mortality, and four cardiac-related death outcomes after primary series COVID-19 vaccination. METHODS: We analyzed all deaths between December 14, 2020, and August 11, 2021, among individuals from eight Vaccine Safety Datalink sites. Demographic characteristics of deaths in recipients of COVID-19 vaccines and unvaccinated individuals were reported. We conducted SCCS analyses by vaccine type and death outcomes and reported relative incidences (RI). The observation period for death spanned from the dates of emergency use authorization to the end of the study period (August 11, 2021) without censoring the observation period upon death. We pre-specified a primary risk interval of 28-day and a secondary risk interval of 14-day after each vaccination dose. Adjusting for seasonality in mortality analyses is crucial because death rates vary over time. Deaths among unvaccinated individuals were included in SCCS analyses to account for seasonality by incorporating calendar month in the models. RESULTS: For Pfizer-BioNTech (BNT162b2), RIs of non-COVID-19 mortality, all-cause mortality, and four cardiac-related death outcomes were below 1 and 95 % confidence intervals (CIs) excluded 1 across both doses and both risk intervals. For Moderna (mRNA-1273), RI point estimates of all outcomes were below 1, although the 95 % CIs of two RI estimates included 1: cardiac-related (RI = 0.78, 95 % CI, 0.58-1.04) and non-COVID-19 cardiac-related mortality (RI = 0.80, 95 % CI, 0.60-1.08) 14 days after the second dose in individuals without pre-existing cancer and heart disease. For Janssen (Ad26.COV2.S), RIs of four cardiac-related death outcomes ranged from 0.94 to 0.98 for the 14-day risk interval, and 0.68 to 0.72 for the 28-day risk interval and 95 % CIs included 1. CONCLUSION: Using a modified SCCS design and adjusting for temporal trends, no-increased risk was found for non-COVID-19 mortality, all-cause mortality, and four cardiac-related death outcomes among recipients of the three COVID-19 vaccines used in the US.
引用
- Xu S, Sy LS, Hong V, et al. Mortality risk after COVID-19 vaccination: A self-controlled case series study. Vaccine. 2024. PMID: 38388239. doi:10.1016/j.vaccine.2024.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。